A mother says her “gut instinct” told her something was wrong with her baby boy immediately after she gave birth — and doctors soon delivered a devastating diagnosis. Hannah Doyle’s son, Zander, was ...
A mother who was puzzled that her newborn looked nothing like her asked doctors to investigate, and was stunned when he was diagnosed with a rare chromosome syndrome. As Hannah Doyle, 36, cradled baby ...
Donna McDonald-McGinn, M.S., CGC, associate director of Clinical Genetics and program director of the "22q and You" Center at The Children's Hospital of Philadelphia, received the Angelo DiGeorge ...
Tokyo Medical and Dental University (TMDU) researchers have discovered that patients with 18q deletion syndrome can experience both cellular and humoral immunodeficiency Tokyo, Japan – Chromosome 18q ...
Brain activity patterns during sleep shed light on the neurobiology behind 22q11.2 Deletion Syndrome
The brain activity patterns during sleep shed light on the neurobiology behind a genetic condition called 22q11.2 Deletion Syndrome (22q11.2DS) and could be used as a biomarker to detect the onset of ...
1p36 deletion syndrome is one of the most common subtelomeric microdeletion disorders, occurring in approximately 1 in 5,000 to 10,000 live births. This chromosomal abnormality results in a broad ...
Noah Wanamaker has learned to communicate well with facial expressions. In his hospital bed at the Sanford Children's Hospital, Noah, 2, is hooked up to a feeding tube, ventilator and an IV, cocooned ...
The research findings imply that patients with genitourinary birth defects due to 22q11.2 changes in gene dosage should also be evaluated for other potential birth defects seen in patients with ...
Hayley Moulding receives funding from the Medical Research Council and is a PhD student at the MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University. Hayley works for The ECHO ...
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aortic valve disease.
Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. ZYNE, completed enrollment for the 14-week Phase 2 INSPIRE trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results